Citadel Advisors
CLVS

Citadel Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Citadel Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-285,800
Closed -$340K – 15847
2022
Q3 		$340K Sell
285,800
-445,600
-61% -$695K ﹤0.01% 9297
2022
Q2 		$1.32M Buy
731,400
+252,300
+53% +$372K ﹤0.01% 6408
2022
Q1 		$968K Buy
479,100
+206,500
+76% +$406K ﹤0.01% 7771
2021
Q4 		$739K Sell
272,600
-94,000
-26% -$347K ﹤0.01% 8696
2021
Q3 		$1.64M Sell
366,600
-231,900
-39% -$1.12M ﹤0.01% 6874
2021
Q2 		$3.47M Sell
598,500
-189,300
-24% -$1.11M ﹤0.01% 5263
2021
Q1 		$5.53M Buy
787,800
+451,500
+134% +$3.03M ﹤0.01% 4036
2020
Q4 		$1.61M Sell
336,300
-154,500
-31% -$781K ﹤0.01% 5833
2020
Q3 		$2.86M Buy
490,800
+170,500
+53% +$1.02M ﹤0.01% 4061
2020
Q2 		$2.16M Sell
320,300
-89,900
-22% -$681K ﹤0.01% 4428
2020
Q1 		$2.61M Buy
410,200
+44,700
+12% +$359K ﹤0.01% 3699
2019
Q4 		$3.81M Buy
365,500
+223,500
+157% +$1.63M ﹤0.01% 3451
2019
Q3 		$558K Buy
142,000
+23,400
+20% +$189K ﹤0.01% 6560
2019
Q2 		$1.76M Sell
118,600
-4,500
-4% -$81.3K ﹤0.01% 4731
2019
Q1 		$3.06M Sell
123,100
-81,100
-40% -$2.03M ﹤0.01% 3729
2018
Q4 		$3.67M Buy
204,200
+77,100
+61% +$1.58M ﹤0.01% 3242
2018
Q3 		$3.73M Buy
127,100
+3,500
+3% +$136K ﹤0.01% 3388
2018
Q2 		$5.62M Buy
123,600
+62,800
+103% +$3.05M ﹤0.01% 2596
2018
Q1 		$3.21M Sell
60,800
-7,400
-11% -$432K ﹤0.01% 3049
2017
Q4 		$4.64M Sell
68,200
-22,600
-25% -$1.58M ﹤0.01% 2557
2017
Q3 		$7.48M Buy
90,800
+8,400
+10% +$666K 0.01% 1886
2017
Q2 		$7.71M Buy
82,400
+28,800
+54% +$1.76M 0.01% 1681
2017
Q1 		$3.41M Sell
53,600
-5,100
-9% -$310K ﹤0.01% 2451
2016
Q4 		$2.61M Buy
58,700
+5,300
+10% +$187K ﹤0.01% 2658
2016
Q3 		$1.93M Sell
53,400
-8,000
-13% -$172K ﹤0.01% 3013
2016
Q2 		$842K Buy
61,400
+3,700
+6% +$54.1K ﹤0.01% 3780
2016
Q1 		$1.11M Buy
57,700
+23,000
+66% +$487K ﹤0.01% 3362
2015
Q4 		$1.22M Buy
34,700
+15,500
+81% +$1,000K ﹤0.01% 3345
2015
Q3 		$1.77M Sell
19,200
-6,700
-26% -$580K ﹤0.01% 3106
2015
Q2 		$2.28M Sell
25,900
-18,600
-42% -$1.59M ﹤0.01% 2921
2015
Q1 		$3.3M Buy
44,500
+14,300
+47% +$1.01M ﹤0.01% 2485
2014
Q4 		$1.69M Sell
30,200
-3,500
-10% -$184K ﹤0.01% 3115
2014
Q3 		$1.53M Sell
33,700
-6,200
-16% -$259K ﹤0.01% 3185
2014
Q2 		$1.65M Buy
39,900
+1,900
+5% +$97.9K ﹤0.01% 2932
2014
Q1 		$2.63M Buy
38,000
+23,400
+160% +$1.72M ﹤0.01% 2374
2013
Q4 		$880K Buy
+14,600
New +$794K ﹤0.01% 3340

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Citadel Advisors's CLVS Position: Q4 2022 in Review

Citadel Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 129,979 shares — an estimated $155K sold.

Citadel Advisors first reported a position in CLVS in Q2 2013 and held it in 34 quarters. The position peaked at $112M in Q3 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Citadel Advisors reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 129,979 Clovis Oncology, Inc. shares in Q4 2022, an estimated $155K.
  • Citadel Advisors first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 34 quarters.
  • Citadel Advisors's Clovis Oncology, Inc. position peaked at $112M in Q3 2017.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.